{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:25:15Z","timestamp":1789118715223,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Guideline-directed medical therapy (GDMT) improves outcomes in heart failure, yet many patients remain undertreated or are not titrated to optimal doses. International evidence shows pharmacist-led heart failure clinics improve GDMT prescribing and reduce hospitalisations, but data in Australian settings are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate whether incorporating a collaborative pharmacist medication prescribing model within a heart failure service improved optimisation of guideline-directed medical therapy (GDMT) in patients with heart failure and ejection fraction\u2009&lt;\u200950% compared with pre-implementation usual care, and to evaluate impacts on service efficiency, hospitalisation, mortality, medication beliefs, and health-related quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>An interrupted time series analysis compared 12-month pre- and post-implementation periods following establishment of a collaborative pharmacist medication prescribing clinic across two community heart failure services. Primary outcomes were the proportion of patients optimised on GDMT at 90 days and at clinic discharge. Secondary outcomes included time between visits, monthly attendance, unscheduled hospitalisations, medication adherence and health related quality of life (HRQoL) assessed with the EuroQoL five-dimension five-level health status instrument visual analogue scale (EQ-VAS) and the Kansas City Cardiomyopathy Questionnaire (KCCQ-12).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 302 patients with ejection fraction\u2009&lt;\u200950% were included, with 98 and 204 patients in the pre- and post-implementation cohort respectively. Overall, 285 patients (94.4%) had a left ventricular ejection fraction\u2009\u2264\u200940%, with similar proportions between cohorts (94.6% vs. 93.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.000). Optimisation of GDMT increased from 19.3% (n\u2009=\u200919) to 40.2% (n\u2009=\u200982) at 90 days (adjusted OR\u2009=\u20092.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), and from 43.9% (n\u2009=\u200943) to 88.2% (n\u2009=\u2009180) at discharge (adjusted OR\u2009=\u200913.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Median time between visits decreased from 49 to 28 days (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while mean monthly attendance increased from 9 to 16 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). HRQoL scores increased within the post-implementation group, measured by the KCCQ-12 (74.0\u2009\u2192\u200984.8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and EQ-VAS (73.0\u2009\u2192\u200979.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). Medication adherence remained high according to self-reported Medication Adherence Report Scale (MARS) scores. No change in hospitalisations or mortality was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Introducing a collaborative pharmacist medication prescribing clinic to usual care was associated with higher rates of GDMT optimisation and increased clinic throughput. These findings support the feasibility of collaborative prescribing models to facilitate GDMT optimisation within Australian health services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02186-0","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:05:48Z","timestamp":1784271948000},"page":"2050-2063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Collaborative pharmacist prescribing in community heart failure clinics: a pre-post intervention comparison"],"prefix":"10.1007","volume":"48","author":[{"given":"Matthew","family":"Percival","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Hattingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Jayasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Millhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"De Wet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"2186_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12913-016-1748-0","volume":"16","author":"YK Chan","year":"2016","unstructured":"Chan YK, Tuttle C, Ball J, et al. Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue. BMC Health Serv Res. 2016;16(1):501. https:\/\/doi.org\/10.1186\/s12913-016-1748-0.","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"2186_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.hlc.2018.06.1042","volume":"27","author":"J Atherton","year":"2018","unstructured":"Atherton J, Sindone A, De Pasquale C, et al. National heart foundation of Australia and cardiac society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. 2018;27(10):1123\u2013208. https:\/\/doi.org\/10.1016\/j.hlc.2018.06.1042.","journal-title":"Heart Lung Circ"},{"issue":"4","key":"2186_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5694\/mja2.51656","volume":"217","author":"AP Sindone","year":"2022","unstructured":"Sindone AP, De Pasquale C, Amerena J, et al. Consensus statement on the current pharmacological prevention and management of heart failure. Med J Aust. 2022;217(4):212\u20137. https:\/\/doi.org\/10.5694\/mja2.51656.","journal-title":"Med J Aust"},{"issue":"17","key":"2186_CR4","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary. J Am Coll Cardiol. 2022;79(17):e263-421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2186_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.15420\/cfr.2017:1:2","volume":"3","author":"JJ Atherton","year":"2017","unstructured":"Atherton JJ, Hickey A. Expert comment: is medication titration in heart failure too complex? Card Fail Rev. 2017;3(1):25\u201332. https:\/\/doi.org\/10.15420\/cfr.2017:1:2.","journal-title":"Card Fail Rev"},{"issue":"1","key":"2186_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2023;26(1):5\u201317. https:\/\/doi.org\/10.1002\/ejhf.3024.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2186_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.sapharm.2019.10.002","volume":"16","author":"K Guirguis","year":"2020","unstructured":"Guirguis K. Prescribed heart failure pharmacotherapy: how closely do GPs adhere to treatment guidelines? Res Social Adm Pharm. 2020;16(7):935\u201340. https:\/\/doi.org\/10.1016\/j.sapharm.2019.10.002.","journal-title":"Res Social Adm Pharm"},{"issue":"18","key":"2186_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/s0735-1097(21)02232-4","volume":"77","author":"A Pensa","year":"2021","unstructured":"Pensa A, Fine M, Wu T, et al. Implementation of a protocol-driven, pharmacist-led, medication adjust and titrate clinic to improve uptake of guideline-directed medical therapy for patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;77(18):873. https:\/\/doi.org\/10.1016\/s0735-1097(21)02232-4.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2186_CR9","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.cardfail.2022.03.324","volume":"28","author":"P McCabe","year":"2022","unstructured":"McCabe P, Feitell S, Parikh V. Implementation of a pharmacist-driven medication optimization service improves heart failure medication doses and diabetes metrics. J Card Fail. 2022;28(5):S126. https:\/\/doi.org\/10.1016\/j.cardfail.2022.03.324.","journal-title":"J Card Fail"},{"issue":"2","key":"2186_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/0897190019866930","volume":"34","author":"A Ingram","year":"2021","unstructured":"Ingram A, Valente M, Dzurec MA. Evaluating pharmacist impact on guideline-directed medical therapy in patients with reduced ejection fraction heart failure. J Pharm Pract. 2021;34(2):239\u201346. https:\/\/doi.org\/10.1177\/0897190019866930.","journal-title":"J Pharm Pract"},{"issue":"6","key":"2186_CR11","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1007\/s12265-022-10262-9","volume":"15","author":"T Patil","year":"2022","unstructured":"Patil T, Ali S, Kaur A, et al. Impact of pharmacist-led heart failure clinic on optimization of guideline-directed medical therapy (PHARM-HF). J Cardiovasc Transl Res. 2022;15(6):1424\u201335. https:\/\/doi.org\/10.1007\/s12265-022-10262-9.","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"2186_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.japh.2021.11.012","volume":"62","author":"SP Shah","year":"2022","unstructured":"Shah SP, Dixit NM, Mendoza K, et al. Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. J Am Pharm Assoc (2003). 2022;62(2):575-9 e2. https:\/\/doi.org\/10.1016\/j.japh.2021.11.012.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2186_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/IPRP.S341621","volume":"10","author":"KO Ahmed","year":"2021","unstructured":"Ahmed KO, Taj Eldin I, Yousif M, et al. Clinical pharmacist\u2019s intervention to improve medication titration for heart failure: first experience from Sudan. Integr Pharm Res Pract. 2021;10:135\u201343. https:\/\/doi.org\/10.2147\/IPRP.S341621.","journal-title":"Integr Pharm Res Pract"},{"issue":"12","key":"2186_CR14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.2146\/ajhp120267","volume":"70","author":"AS Martinez","year":"2013","unstructured":"Martinez AS, Saef J, Paszczuk A, et al. Implementation of a pharmacist-managed heart failure medication titration clinic. Am J Health Syst Pharm. 2013;70(12):1070\u20136. https:\/\/doi.org\/10.2146\/ajhp120267.","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"2186_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1177\/1060028018760568","volume":"52","author":"S Bhat","year":"2018","unstructured":"Bhat S, Kansal M, Kondos GT, et al. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. Ann Pharmacother. 2018;52(8):724\u201332. https:\/\/doi.org\/10.1177\/1060028018760568.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2186_CR16","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/bcp.70261","volume":"91","author":"L Van der Linden","year":"2025","unstructured":"Van der Linden L, Beavers C, Forsyth P, et al. Effects of pharmacist care on hospitalizations in heart failure across outpatient and inpatient settings: a systematic review and meta-analysis. Br J Clin Pharmacol. 2025;91(11):3021\u201330. https:\/\/doi.org\/10.1002\/bcp.70261.","journal-title":"Br J Clin Pharmacol"},{"key":"2186_CR17","unstructured":"Queensland Health. Queensland Health Collaborative Pharmacist Medication Prescribing Framework 2025 [cited 15.10.2025]. Available from: https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0035\/1441799\/Queensland-Health-Collaborative-Pharmacist-Medication-Prescribing-Framework.pdf."},{"issue":"7","key":"2186_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/ajhp\/zxaa012","volume":"77","author":"YH Bae-Shaaw","year":"2020","unstructured":"Bae-Shaaw YH, Eom H, Chun RF, et al. Real-world evidence on impact of a pharmacist-led transitional care program on 30- and 90-day readmissions after acute care episodes. Am J Health Syst Pharm. 2020;77(7):535\u201345. https:\/\/doi.org\/10.1093\/ajhp\/zxaa012.","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"2186_CR19","doi-asserted-by":"publisher","first-page":"e2453976","DOI":"10.1001\/jamanetworkopen.2024.53976","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Zhao Y, Han L, et al. Pharmacist-led management model and medication adherence among patients with chronic heart failure: a randomized clinical trial. JAMA Netw Open. 2024;7(12):e2453976. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.53976.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2186_CR20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245\u201355. https:\/\/doi.org\/10.1016\/s0735-1097(00)00531-3.","journal-title":"J Am Coll Cardiol"},{"issue":"e1","key":"2186_CR21","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1136\/ejhpharm-2021-002869","volume":"30","author":"G Campbell","year":"2023","unstructured":"Campbell G, Razouk R, Auyeung V, et al. Evaluation of the impact of the addition of a heart failure prescribing pharmacist to consultant-led heart failure ward round at a tertiary hospital. Eur J Hosp Pharm. 2023;30(e1):e14\u20138. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002869.","journal-title":"Eur J Hosp Pharm"},{"issue":"Suppl 2","key":"2186_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s41687-021-00369-z","volume":"5","author":"K Churchill","year":"2021","unstructured":"Churchill K, Warner L, Keogh E, et al. Implementation of EQ-5D-5L as a routine outcome measure in community outpatient and specialized rehabilitation services. J Patient Report Outcomes. 2021;5(Suppl 2):103. https:\/\/doi.org\/10.1186\/s41687-021-00369-z.","journal-title":"J Patient Report Outcomes"},{"issue":"4","key":"2186_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/ehjqcco\/qcab014","volume":"7","author":"M Thomas","year":"2021","unstructured":"Thomas M, Jones PG, Cohen DJ, et al. Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. Eur Heart J. 2021;7(4):388\u201396. https:\/\/doi.org\/10.1093\/ehjqcco\/qcab014.","journal-title":"Eur Heart J"},{"issue":"12","key":"2186_CR24","doi-asserted-by":"publisher","first-page":"e80633","DOI":"10.1371\/journal.pone.0080633","volume":"8","author":"R Horne","year":"2013","unstructured":"Horne R, Chapman SC, Parham R, et al. Understanding patients\u2019 adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS ONE. 2013;8(12):e80633. https:\/\/doi.org\/10.1371\/journal.pone.0080633.","journal-title":"PLoS ONE"},{"issue":"6","key":"2186_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s0022-3999(99)00057-4","volume":"47","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J. Patients\u2019 beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555\u201367. https:\/\/doi.org\/10.1016\/s0022-3999(99)00057-4.","journal-title":"J Psychosom Res"},{"issue":"1","key":"2186_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870449908407311","volume":"14","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1\u201324. https:\/\/doi.org\/10.1080\/08870449908407311.","journal-title":"Psychol Health"},{"key":"2186_CR27","unstructured":"American Heart Association. Classes and Stages of Heart Failure 2025 [cited 15.10.2025]. Available from: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/classes-of-heart-failure."},{"issue":"6","key":"2186_CR28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/jppr.1959","volume":"54","author":"M Dooley","year":"2024","unstructured":"Dooley M, Bennett G, Clayson\u2010Fisher T, et al. Advanced pharmacy Australia clinical pharmacy standards. J Pharm Pract Res. 2024;54(6):446\u2013511. https:\/\/doi.org\/10.1002\/jppr.1959.","journal-title":"J Pharm Pract Res"},{"key":"2186_CR29","doi-asserted-by":"publisher","first-page":"g1687","DOI":"10.1136\/bmj.g1687","volume":"348","author":"TC Hoffmann","year":"2014","unstructured":"Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. https:\/\/doi.org\/10.1136\/bmj.g1687.","journal-title":"BMJ"},{"issue":"1","key":"2186_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2307\/2951684","volume":"60","author":"R Cumby","year":"1992","unstructured":"Cumby R, Huizinga J. Testing the autocorrelation structure of disturbances in ordinary least squares and instrumental variables regressions. Econometrica. 1992;60(1):185\u201395.","journal-title":"Econometrica"},{"key":"2186_CR31","doi-asserted-by":"publisher","first-page":"h2750","DOI":"10.1136\/bmj.h2750","volume":"350","author":"E Kontopantelis","year":"2015","unstructured":"Kontopantelis E, Doran T, Springate DA, et al. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. BMJ. 2015;350:h2750. https:\/\/doi.org\/10.1136\/bmj.h2750.","journal-title":"BMJ"},{"issue":"1","key":"2186_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ije\/dyw098","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348\u201355. https:\/\/doi.org\/10.1093\/ije\/dyw098.","journal-title":"Int J Epidemiol"},{"issue":"8","key":"2186_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010.","journal-title":"Ann Intern Med"},{"issue":"10367","key":"2186_CR34","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1.","journal-title":"Lancet"},{"issue":"4","key":"2186_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2186_CR36","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","volume":"23","author":"G Savarese","year":"2021","unstructured":"Savarese G, Bodegard J, Norhammar A, et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail. 2021;23(9):1499\u2013511. https:\/\/doi.org\/10.1002\/ejhf.2271.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2186_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11096-024-01808-9","volume":"47","author":"G Campbell","year":"2025","unstructured":"Campbell G, Doherty C, D\u2019Silva A, et al. Implementation and evaluation of specialist heart failure pharmacist prescribing clinics. Int J Clin Pharm. 2025;47(1):8\u201314. https:\/\/doi.org\/10.1007\/s11096-024-01808-9.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"2186_CR38","doi-asserted-by":"publisher","first-page":"e0000868","DOI":"10.1371\/journal.pdig.0000868","volume":"4","author":"H Alhakem","year":"2025","unstructured":"Alhakem H, Murphy A, Fusco L, et al. Pharmacist-led rapid uptitration clinic in heart failure patients with reduced ejection fraction: our experience within a virtual ward. PLoS Digit Health. 2025;4(6):e0000868. https:\/\/doi.org\/10.1371\/journal.pdig.0000868.","journal-title":"PLoS Digit Health"},{"issue":"6","key":"2186_CR39","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11096-024-01790-2","volume":"46","author":"A Thomas","year":"2024","unstructured":"Thomas A, Forsyth P, Griffiths C, et al. Implementation and evaluation of pharmacist-led heart failure diagnostic and guideline directed medication therapies clinic. Int J Clin Pharm. 2024;46(6):1247\u201355. https:\/\/doi.org\/10.1007\/s11096-024-01790-2.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"2186_CR40","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/jac5.1219","volume":"3","author":"B Atallah","year":"2020","unstructured":"Atallah B, Sadik ZG, Osoble AA, et al. Establishing the first pharmacist\u2010led heart failure medication optimization clinic in the Middle East Gulf Region. J Am Coll Clin Pharm. 2020;3(5):877\u201384. https:\/\/doi.org\/10.1002\/jac5.1219.","journal-title":"J Am Coll Clin Pharm"},{"issue":"7","key":"2186_CR41","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/jac5.1450","volume":"4","author":"VFS Cao","year":"2021","unstructured":"Cao VFS, Cowley E, Koshman SL, et al. Pharmacist\u2010led optimization of heart failure medications: a systematic review. J Am Coll Clin Pharm. 2021;4(7):862\u201370. https:\/\/doi.org\/10.1002\/jac5.1450.","journal-title":"J Am Coll Clin Pharm"},{"issue":"1","key":"2186_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12875-023-02256-6","volume":"25","author":"S Javanparast","year":"2024","unstructured":"Javanparast S, Roeger L, Reed RL. General practice staff and patient experiences of a multicomponent intervention for people at high risk of poor health outcomes: a qualitative study. BMC Prim Care. 2024;25(1):18. https:\/\/doi.org\/10.1186\/s12875-023-02256-6.","journal-title":"BMC Prim Care"},{"issue":"6","key":"2186_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.7861\/clinmed.2019-0263","volume":"19","author":"G Caldwell","year":"2019","unstructured":"Caldwell G. The process of clinical consultation is crucial to patient outcomes and safety: 10 quality indicators. Clin Med (Lond). 2019;19(6):503\u20136. https:\/\/doi.org\/10.7861\/clinmed.2019-0263.","journal-title":"Clin Med (Lond)"},{"issue":"6524","key":"2186_CR44","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/bmj.292.6524.870","volume":"292","author":"DC Morrell","year":"1986","unstructured":"Morrell DC, Evans ME, Morris RW, et al. The \u201cfive minute\u201d consultation: effect of time constraint on clinical content and patient satisfaction. Br Med J (Clin Res Ed). 1986;292(6524):870\u20133. https:\/\/doi.org\/10.1136\/bmj.292.6524.870.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6679","key":"2186_CR45","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/bmj.298.6679.1008","volume":"298","author":"JG Howie","year":"1989","unstructured":"Howie JG, Porter AM, Forbes JF. Quality and the use of time in general practice: widening the discussion. BMJ. 1989;298(6679):1008\u201310. https:\/\/doi.org\/10.1136\/bmj.298.6679.1008.","journal-title":"BMJ"},{"issue":"411","key":"2186_CR46","first-page":"601","volume":"46","author":"R Baker","year":"1996","unstructured":"Baker R. Characteristics of practices, general practitioners and patients related to levels of patients\u2019 satisfaction with consultations. Br J Gen Pract. 1996;46(411):601\u20135.","journal-title":"Br J Gen Pract"},{"key":"2186_CR47","doi-asserted-by":"publisher","unstructured":"Wilson AD, Childs S. Effects of interventions aimed at changing the length of primary care physicians\u2019 consultation. Cochrane Database Syst Rev. 2006;(1):003540. https:\/\/doi.org\/10.1002\/14651858.CD003540.pub2","DOI":"10.1002\/14651858.CD003540.pub2"},{"issue":"4","key":"2186_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/ijpp.12080","volume":"22","author":"D Jorgenson","year":"2014","unstructured":"Jorgenson D, Laubscher T, Lyons B, et al. Integrating pharmacists into primary care teams: barriers and facilitators. Int J Pharm Pract. 2014;22(4):292\u20139. https:\/\/doi.org\/10.1111\/ijpp.12080.","journal-title":"Int J Pharm Pract"},{"issue":"5","key":"2186_CR49","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1345\/aph.1D419","volume":"38","author":"AJ Zillich","year":"2004","unstructured":"Zillich AJ, McDonough RP, Carter BL, et al. Influential characteristics of physician\/pharmacist collaborative relationships. Ann Pharmacother. 2004;38(5):764\u201370. https:\/\/doi.org\/10.1345\/aph.1D419.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2186_CR50","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3109\/13561820.2011.585725","volume":"25","author":"C Van","year":"2011","unstructured":"Van C, Mitchell B, Krass I. General practitioner-pharmacist interactions in professional pharmacy services. J Interprof Care. 2011;25(5):366\u201372. https:\/\/doi.org\/10.3109\/13561820.2011.585725.","journal-title":"J Interprof Care"},{"issue":"4","key":"2186_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.sapharm.2005.09.005","volume":"1","author":"WR Doucette","year":"2005","unstructured":"Doucette WR, Nevins J, McDonough RP. Factors affecting collaborative care between pharmacists and physicians. Res Social Adm Pharm. 2005;1(4):565\u201378. https:\/\/doi.org\/10.1016\/j.sapharm.2005.09.005.","journal-title":"Res Social Adm Pharm"},{"key":"2186_CR52","unstructured":"Australian Government. About Australia's rural health workforce: Australian Government. Department of Health, Disability, and Ageing; 2021 [cited 12.11.2025]. Available from: https:\/\/www.health.gov.au\/topics\/rural-health-workforce\/about#status-of-rural-health-in-australia."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02186-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02186-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:19Z","timestamp":1789117099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02186-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02186-0","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Human Research Ethics Committees at the GCHHS and University of Queensland (Reference Number: HREC\/2023\/QGC\/91934) on 20th April 2023. Reporting following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. [\n                      \n                      ]","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"A waiver of consent was granted for collection of routine clinical data in both the pre-implementation and post-implementation cohorts. Written informed consent was obtained from participants completing non-routine patient-reported outcome questionnaires in the post-implementation cohort.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}